Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

other applicable criteria for continued listing on The NASDAQ Capital Market, but for the $1.00 bid price requirement, which has been suspended by NASDAQ through August 2, 2009. If the application is approved, the company will no longer be subject to delisting from NASDAQ as a result of the previously disclosed stockholders' equity deficiency as of December 31, 2008, but it will need to comply with The NASDAQ Capital Markets' continued listing requirements on an ongoing basis.

Financial Highlights

  • Revenues for the three and six months ended June 30, 2009 were $3.5 million and $3.7 million compared to $2.6 million and $4.9 million for the same periods in 2008. Sunesis recognized $2.0 million in the second quarter of 2009 for the sale to SARcode of its interest in the lymphocyte function-associated antigen-1, or LFA-1, patents and related know-how that had previously been the subject of a license agreement with them, and $1.5 million for the Biogen Idec Raf kinase inhibitor milestone referred to above. Revenues in the 2008 periods were primarily related to research funding under the Biogen Idec collaboration.
  • Research and development expenses decreased to $3.4 million and $7.7 million for the three and six months ended June 30, 2009 from $8.3 million and $17.0 million for the same periods in 2008. The decreases were primarily due to savings from the termination of substantially all discovery research activities in June 2008.
  • General and administrative expenses for the first three and six months of 2009 were $2.0 million and $4.3 million compared to $3.2 million and $6.5 million for the same periods in 2008. The decreases were primarily due to reduced administrative headcount and facility costs as a result of the company's June 2008 and March 2009 restructurings.
  • Restructuring charges of $1.9 million were recorded in the first half o
    '/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... LAS VEGAS, NEVADA, Feb. 6 /PRNewswire-FirstCall/ - Diagnostic Imaging,International ... the,Company stock symbol has been cleared for quotation on ... Additionally the Company announced today that the corporate ... Company plans to work diligently to build on its ...
... Feb. 6 The Global Probiotics Council,(GPC), a ... Yakult Honsha,Co., Ltd., announced the Young Investigator Grant ... grants are designed to stimulate,innovative research and to ... United States into the field of probiotics and ...
... to Recognize Exemplary Work, BRIDGEWATER, N.J., Feb. ... nurses, Ortho Biotech Products, L. P.,today announced its ... Oncology Nursing, which honors one of the thousands ... compassion and helpfulness. Last year, more than 200 ...
Cached Biology Technology:Diagnostic Imaging - New Stock Symbol - OTCBB: DIIG 2Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 2Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 3Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research 4Call for Entries - 2008 CURE Extraordinary Healer Award for Oncology Nursing 2
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... cancer,patients have an abnormality in a specific cell ... pathway may be,especially effective for treating the disease, ... D. Anderson Cancer Center.", , A clearer picture ... 3 kinase (PI3K),pathway to breast cancer development, says ...
... got updated to version 5.0. Proteins are classified,by ... known,pathways. Its main use is probably microarray analysis ... output. Best of,all, its available freely . ... freely in the Nucleic acids research Journal . ...
... An estrogen-like chemical,commonly used to synthesize plastic food ... a specific category of prostate cancer cell,potentially affecting ... to a study published in the January 1 ... to be vulnerable to,exposure to the chemical BPA ...
Cached Biology News:PANTHER Protein Classification System Database 5.0 2PANTHER Protein Classification System Database 5.0 3Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells 2
...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... Resistant (X/R) Red System consists of ... Activator and X/R Red Buffer. The ... phosphatase to produce red staining that ... Contains:, , Buffer, 100 mL , ...
Human Cell Line Slides...
Biology Products: